Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

64.65EUR
6:04am EDT
Change (% chg)

€1.82 (+2.90%)
Prev Close
€62.83
Open
€62.81
Day's High
€64.66
Day's Low
€62.81
Volume
578,197
Avg. Vol
1,089,280
52-wk High
€65.53
52-wk Low
€35.10

FREG.DE

Chart for FREG.DE

About

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments... (more)

Overall

Beta: 0.42
Market Cap(Mil.): €34,146.77
Shares Outstanding(Mil.): 543.48
Dividend: 0.44
Yield (%): 0.70

Financials

  FREG.DE Industry Sector
P/E (TTM): 30.11 16.76 40.68
EPS (TTM): 2.09 -- --
ROI: 7.56 2.61 15.78
ROE: 12.02 2.84 16.82
Search Stocks

Fresenius raises 2015 profit guidance on generic infusion drugs

FRANKFURT - German healthcare group Fresenius SE on Wednesday lifted its full-year earnings target for the second time as its rivals in the U.S. generic infusion drug market struggled with longer-than-expected production outages.

29 Jul 2015

Fresenius raises 2015 profit guidance on generic infusion drugs

FRANKFURT, July 29 - German healthcare group Fresenius SE on Wednesday lifted its full-year earnings target for the second time as its rivals in the U.S. generic infusion drug market struggled with production outages longer than expected.

29 Jul 2015

BRIEF-Fresenius CEO says has no assets to sell

* Ceo says we have no assets to sell; overheated m&a market is no reason to sell assets Further company coverage:

20 May 2015

Fresenius ups profit forecast on higher infusion drug sales

FRANKFURT, April 29 - German healthcare group Fresenius SE lifted its full-year earnings forecast as its rivals in the U.S. generic infusion drug market grappled with supply shortages longer than expected.

29 Apr 2015

Fresenius CEO says to sit out healthcare deal wave

MUNICH - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.

22 Apr 2015

Fresenius CEO says to sit out healthcare deal wave

MUNICH, April 22 - German healthcare group Fresenius will lie in wait for an overheated healthcare deal market to cool down before making further larger acquisitions, its chief executive said.

22 Apr 2015

MDL Watch: Syngenta, Xarelto and Fresenius suits see gains in April

- A Reuters' analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation showed the biggest increases in recent filings over Syngenta genetically modified corn, Bayer and Janssen's blood thinner Xarelto and dialysis drugs made by Fresenius.

21 Apr 2015

Rhoen Klinikum to buy back more shares, boost dividend

FRANKFURT, April 16 - German hospitals operator Rhoen Klinikum AG plans to buy back more shares and boost its dividend payout to distribute to shareholders more of the proceeds from the sale of hospitals to peer Fresenius SE .

16 Apr 2015

BRIEF-Fresenius SE CEO says not the time for large takeovers

* Says to focus on small and medium sized takeovers, not the time for large takeovers

25 Feb 2015

Fresenius sees 2015 adjusted net income up 9-12 pct

FRANKFURT, Feb 25 - German healthcare group Fresenius SE expects its adjusted net income to rise between 9 and 12 percent at constant currencies this year, helped by additional earnings from the purchase of new hospitals and demand for healthcare services.

25 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Finlabo SIM Spa
$10.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$125.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks